AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease Results show, for…
LAVAL, QC / ACCESS Newswire / December 8, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company") announced today the…
NEW YORK, Dec. 8, 2025 /PRNewswire/ -- Imre today announced the appointment of Nadine Lafond as its new Chief Executive…
All closing requirements satisfied following announcement of a non-binding term-sheet agreement in July and signing of contract in NovemberAgreement includes…
Phase 2 results selected as one of only 10 featured presentations in the Poster Tour at the 2025 Parkinson Study…
—Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs)…
Monthly reductions in seizure frequency of 90.9% among participants treated for ≥48 months in the OLE, with 38% achieving ≥1…
Post-hoc analysis of RAP-219 Phase 2a data showed early onset of action and consistency of median response over the entire…
First video-documented ALS reversal marks a new era for brain health achieved through noninvasive computerized brain-temperature modulation, confirmed by electrophysiological,…
Phase 2 clinical trial initiated to evaluate SEMA3A mAb as potential treatment for Alport syndromeMilestone payment to Evotec expected upon…